Alyeska Investment Group
TNDM icon

Alyeska Investment Group’s Tandem Diabetes Care TNDM Stock Holding History

Alyeska Investment Group’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50,021
Closed -$3.18M – 520
2019
Q1 		$3.18M Buy
+50,021
New +$2.63M 0.04% 254
2018
Q4 		– Sell
-20,000
Closed -$857K – 460
2018
Q3 		$857K Buy
+20,000
New +$698K 0.01% 358
2018
Q1 		– Sell
-139,196
Closed -$449K – 512
2017
Q4 		$329K Buy
+139,196
New +$437K ﹤0.01% 413
2017
Q2 		– Sell
-160,000
Closed -$1.92M – 545
2017
Q1 		$1.92M Buy
+160,000
New +$3.5M 0.02% 399

Other funds holding TNDM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Alyeska Investment Group's TNDM Position: Q2 2019 in Review

Alyeska Investment Group sold out of Tandem Diabetes Care (TNDM) in Q2 2019, closing a stake of 50,021 shares — an estimated $3.18M sold.

Alyeska Investment Group first reported a position in TNDM in Q1 2017 and held it in 4 quarters. The position peaked at $3.18M in Q1 2019. 261 funds tracked by Wall St. Rank hold TNDM as of Q2 2019.

  • Alyeska Investment Group reported no remaining Tandem Diabetes Care position as of Q2 2019 after selling out during the quarter.
  • Alyeska Investment Group sold 50,021 Tandem Diabetes Care shares in Q2 2019, an estimated $3.18M.
  • Alyeska Investment Group first reported a position in Tandem Diabetes Care in Q1 2017 and held it in 4 quarters.
  • Alyeska Investment Group's Tandem Diabetes Care position peaked at $3.18M in Q1 2019.
  • 261 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2019.

Based on Alyeska Investment Group's 13F filing for Q2 2019, filed 14 Aug 2019.